| Revision as of 16:58, 20 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit | Latest revision as of 13:42, 16 October 2022 edit undo147.147.108.194 (talk) Removing advertisingTag: references removed | ||
| (23 intermediate revisions by 19 users not shown) | |||
| Line 1: | Line 1: | ||
| {{chembox | {{chembox | ||
| | Verifiedfields = changed | |||
| | verifiedrevid = |
| verifiedrevid = 425029276 | ||
| |ImageFile=U46619.png | | ImageFile=U46619.png | ||
| |ImageSize=200px | | ImageSize=200px | ||
| | |
| PIN=(5''Z'')-7-<nowiki/>{(1''R'',4''S'',5''S'',6''R'')-6--2-oxabicycloheptan-5-yl}hept-5-enoic acid | ||
| |OtherNames= | | OtherNames= | ||
| |Section1={{Chembox Identifiers | |Section1={{Chembox Identifiers | ||
| | CASNo_Ref = {{cascite|correct|??}} | |||
| | |
| CASNo=56985-40-1 | ||
| | |
| PubChem=5311493 | ||
| | ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| | ChEMBL = 357834 | |||
| | IUPHAR_ligand = 1888 | | IUPHAR_ligand = 1888 | ||
| | |
| SMILES=CCCCC(O)/C=C/12OC(C2)1C/C=C\CCCC(O)=O | ||
| }} | }} | ||
| |Section2={{Chembox Properties | |Section2={{Chembox Properties | ||
| | |
| Formula=C<sub>21</sub>H<sub>34</sub>O<sub>4</sub> | ||
| | |
| MolarMass=350.49 g/mol | ||
| | |
| Appearance= | ||
| | |
| Density= | ||
| | |
| MeltingPt= | ||
| | |
| BoilingPt= | ||
| | |
| Solubility= | ||
| }} | }} | ||
| |Section3={{Chembox Hazards | |Section3={{Chembox Hazards | ||
| | |
| MainHazards= | ||
| | |
| FlashPt= | ||
| | AutoignitionPt = | |||
| | Autoignition= | |||
| }} | }} | ||
| }} | }} | ||
| '''U46619''' is a stable synthetic ] of the ] PGH<sub>2</sub> first prepared in 1975 |
'''U46619''' is a stable synthetic ] of the endoperoxide ] PGH<sub>2</sub> first prepared in 1975,<ref>{{cite journal | author = Bundy, G. L. | title = Synthesis of prostaglandin endoperoxide analogs | journal = Tetrahedron Letters | year = 1975 | volume = 16 | pages = 1957–1960 | doi = 10.1016/S0040-4039(00)72333-1 | issue = 24}}</ref> and acts as a thromboxane A<sub>2</sub> (TP) receptor agonist. It potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations and exhibits many properties similar to thromboxane A<sub>2</sub>, including shape change and aggregation of platelets <ref>{{cite journal | title=Binding of a thromboxane A2/prostaglandin H2 agonist U46619 to washed human platelets |author1=Liel, N. |author2=Mais, D.E. |author3=Halushka, P.V | journal = Prostaglandins | year=1987 |volume=33|issue=6 |pages= 789–797 | doi=10.1016/0090-6980(87)90107-9|pmid=2959986 }}</ref> and smooth muscle contraction. U46619 is a ] that mimics the hydroosmotic effect of ].<ref>{{cite journal | title = Calcium-45 fluxes in isolated toad bladder epithelial cells: effects of agents which alter water or sodium transport |author1=Burch, Ronald M. |author2=Halushka, Perry V. | journal = Journal of Pharmacology and Experimental Therapeutics |year=1983|volume =224|issue=1|pages= 108–17 | pmid = 6294273}}</ref> | ||
| ==References== | ==References== | ||
| {{ |
{{Reflist|2}} | ||
| {{Prostanoidergics}} | |||
| ] | ] | ||
| {{Molecular-biology-stub}} | |||
Latest revision as of 13:42, 16 October 2022
| |
| Names | |
|---|---|
| Preferred IUPAC name (5Z)-7-{(1R,4S,5S,6R)-6--2-oxabicycloheptan-5-yl}hept-5-enoic acid | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| ChEMBL | |
| ECHA InfoCard | 100.164.944 
|
| IUPHAR/BPS | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
SMILES
| |
| Properties | |
| Chemical formula | C21H34O4 |
| Molar mass | 350.49 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
 N verify (what is ?)
Infobox references
| |
U46619 is a stable synthetic analog of the endoperoxide prostaglandin PGH2 first prepared in 1975, and acts as a thromboxane A2 (TP) receptor agonist. It potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations and exhibits many properties similar to thromboxane A2, including shape change and aggregation of platelets and smooth muscle contraction. U46619 is a vasoconstrictor that mimics the hydroosmotic effect of vasopressin.
References
- Bundy, G. L. (1975). "Synthesis of prostaglandin endoperoxide analogs". Tetrahedron Letters. 16 (24): 1957–1960. doi:10.1016/S0040-4039(00)72333-1.
- Liel, N.; Mais, D.E.; Halushka, P.V (1987). "Binding of a thromboxane A2/prostaglandin H2 agonist U46619 to washed human platelets". Prostaglandins. 33 (6): 789–797. doi:10.1016/0090-6980(87)90107-9. PMID 2959986.
- Burch, Ronald M.; Halushka, Perry V. (1983). "Calcium-45 fluxes in isolated toad bladder epithelial cells: effects of agents which alter water or sodium transport". Journal of Pharmacology and Experimental Therapeutics. 224 (1): 108–17. PMID 6294273.
 | This molecular biology article is a stub. You can help Misplaced Pages by expanding it. |